Demirci E - Search Results

1

Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.

Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Araman A, Kanmaz B. Ocak M, et al. Among authors: demirci e. Nucl Med Commun. 2013 Nov;34(11):1084-9. doi: 10.1097/MNM.0b013e328364eaab. Nucl Med Commun. 2013. PMID: 23939265

2

Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.

Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, Uslu I, Kanmaz B. Kabasakal L, et al. Among authors: demirci e. Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1271-7. doi: 10.1007/s00259-012-2123-y. Epub 2012 Apr 20. Eur J Nucl Med Mol Imaging. 2012. PMID: 22526963

3

Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.

Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B. Demirci E, et al. Nucl Med Commun. 2013 Aug;34(8):727-32. doi: 10.1097/MNM.0b013e328362cca6. Nucl Med Commun. 2013. PMID: 23728519

4

Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme.

Oborski MJ, Demirci E, Laymon CM, Lieberman FS, Mountz JM. Oborski MJ, et al. Among authors: demirci e. Clin Nucl Med. 2014 Oct;39(10):e431-2. doi: 10.1097/RLU.0000000000000321. Clin Nucl Med. 2014. PMID: 24368529

5

(68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halaç M, Kanmaz B. Demirci E, et al. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1461-2. doi: 10.1007/s00259-014-2766-y. Epub 2014 Apr 23. Eur J Nucl Med Mol Imaging. 2014. PMID: 24756358 No abstract available.

6

Dual false positive of ⁶⁸Ga-DOTA-TATE PET/CT scan in a patient with a history of pancreatic neuroendocrine tumor: a case report.

Demirci E, Akyel R, Kilic F, Kantarci F, Halac M, Sonmezoglu K. Demirci E, et al. Rev Esp Med Nucl Imagen Mol. 2015 Mar-Apr;34(2):133-5. doi: 10.1016/j.remn.2014.03.005. Epub 2014 May 22. Rev Esp Med Nucl Imagen Mol. 2015. PMID: 24857626 No abstract available.

7

Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.

Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, Halac M, Talat Z, Araman A. Kabasakal L, et al. Among authors: demirci e. Nucl Med Commun. 2015 Jun;36(6):582-7. doi: 10.1097/MNM.0000000000000290. Nucl Med Commun. 2015. PMID: 25738559

8

Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.

Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Kabasakal L, et al. Among authors: demirci e. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976-83. doi: 10.1007/s00259-015-3125-3. Epub 2015 Jul 31. Eur J Nucl Med Mol Imaging. 2015. PMID: 26227531

9

Clinical, pathological and (18)F-FDG PET/CT findings in synchronous primary vaginal and endometrial cancers.

Gunes BY, Akbayır O, Demirci E, Ozaydin I. Gunes BY, et al. Among authors: demirci e. Hell J Nucl Med. 2016 May-Aug;19(2):170-2. doi: 10.1967/s002449910374. Epub 2016 Jun 22. Hell J Nucl Med. 2016. PMID: 27331214

10

Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.

Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Demirci E, et al. Nucl Med Commun. 2016 Nov;37(11):1169-79. doi: 10.1097/MNM.0000000000000566. Nucl Med Commun. 2016. PMID: 27333090

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

200 results

Search Page

Filters